An announcement from Roquefort Investments PLC ( (GB:ROQ) ) is now available.
Roquefort Therapeutics PLC has announced the signing of a term sheet for the proposed sale of its wholly-owned subsidiary, Oncogeni Ltd, to Nations Trust Holding LLC for up to $12 million. This transaction aligns with Roquefort’s strategy to acquire and develop pre-clinical assets and realize value through trade-sale transactions. The sale will allow Oncogeni’s portfolio, which includes exclusive licenses to Mesodermal Killer cell and STAT-6 siRNA patents, to advance into clinical trials under the management of a well-funded partner, potentially creating long-term value for Roquefort.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the Main Market, focusing on developing first-in-class drugs in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel, patent-protected pre-clinical anti-cancer and immunology assets.
YTD Price Performance: -61.73%
Average Trading Volume: 1,417,075
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.1M
For a thorough assessment of ROQ stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com